---
title: "SYNERGY: Mirabegron has obtained the drug registration certificate in South Korea"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/228546268.md"
description: "According to the Zhitong Finance APP, SYNERGY announced that the company recently received the Mirabegron drug registration certificate issued by the Ministry of Food and Drug Safety (MFDS) of South Korea. Mirabegron is a selective β3-adrenergic receptor agonist that can improve bladder filling and storage capacity by activating β3-adrenergic receptors on the bladder detrusor muscle. It is clinically used to treat symptoms of overactive bladder, such as urgency urinary incontinence, urinary urgency, and urinary frequency"
datetime: "2025-02-17T10:35:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/228546268.md)
  - [en](https://longbridge.com/en/news/228546268.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/228546268.md)
generator: "portal-rs"
---

# SYNERGY: Mirabegron has obtained the drug registration certificate in South Korea

According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that the company recently received the Mirabegron drug registration certificate issued by the Ministry of Food and Drug Safety (MFDS) of South Korea. Mirabegron is a selective β3-adrenergic receptor agonist that can enhance bladder filling and storage capacity by activating β3-adrenergic receptors on the bladder detrusor muscle, and is clinically used to treat symptoms of overactive bladder such as urgency urinary incontinence, urinary urgency, and urinary frequency

### Related Stocks

- [300636.CN](https://longbridge.com/en/quote/300636.CN.md)

## Related News & Research

- [Alibaba’s AI Spending Spree Intensifies — Surprise Stock Sale Has Analysts Asking Why](https://longbridge.com/en/news/296767766.md)
- [Trump Sends Saudi Nuclear Deal to Congress as Expert Warns of 'Slippery Slope' Toward Wider Nuclear Proliferation](https://longbridge.com/en/news/297016760.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)
- [BMS Holdings Q4 FY2026 PAT Rises 106.5% QoQ to RM5.04 Million](https://longbridge.com/en/news/296892849.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**